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Mg2+ dependent nucleaseEukaryotic mRNA contains a 30 poly(A) tail, which plays important roles in the regulation of mRNA
stability and translation. Well-characterized enzymes involved in the shortening of the poly(A) tail
include the multi-subunit Ccr4-Not deadenylase, which contains the Caf1 (Pop2) and Ccr4 catalytic
components, and poly(A)-specific ribonuclease (PARN). Two Mg2+ ions present in the active sites of these
ribonucleases are required for RNA cleavage. Here, we report the discovery, synthesis and biochemical
profiling of purine-2,6-dione derivatives as (sub)micromolar inhibitors of Caf1.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).In eukaryotic cells, cytoplasmic mRNA is characterized by the
presence of a 30 poly(A) tail. The median length of the tail varies
from 27 to 28 nucleotides in yeast to 60–100 nucleotides in
mammalian cells.1,2 The tail is important for the control of gene
expression: enzymatic shortening of the poly(A) tail (deadenyla-
tion) can initiate mRNA degradation and repress translation.3 An
important enzyme involved in cytoplasmic deadenylation is the
multi-component Ccr4-Not complex.4,5 In addition to six non-
catalytic subunits, the complex contains two subunits with ribonu-
clease activity: both Caf1 and Ccr4 display Mg2+-dependent 30–50
exo-ribonuclease activity with a preference for poly(A). However,
whereas the enzymatic activity of Caf1 is associated with an
RNAse D/DEDD (Asp-Glu-Asp-Asp) domain,6–8 the enzymatic
activity of Ccr4 is provided by an EEP (endonuclease-exonucle-
ase-phosphatase) domain.9,10The analysis of genetically modified mice has identified the
importance of Ccr4-Not subunits in the regulation of physiological
functions such as bone formation and male fertility11,12 as well as
obesity and heart disease.13,14 Moreover, mutations in CNOT3
are frequently identified in acute lymphoblastic leukemia.15
Currently, it is unclear whether the ribonuclease activities of the
Ccr4-Not complex are involved in the regulation of these processes
and to what extent the Caf1 and Ccr4 subunits have unique roles,
or cooperate in deadenylation.16–18 Because the structural com-
plexity of the Ccr4-Not deadenylase is a significant barrier to dis-
tinguishing between catalytic and structural roles of the
complex, additional tools to study Ccr4-Not function are required.
In particular, cell-permeable small-molecule inhibitors that selec-
tively inhibit the enzyme activities of Caf1 or Ccr4 are desirable
as a complementary approach to RNAi and genetic techniques.
Such molecules will be highly useful as pharmacological tools to
study the involvement of the catalytic activity of Ccr4-Not in
physiological processes, and contribute to the evaluation of this
complex as a potential therapeutic target.
While nucleoside analogues have been reported as inhibitors of
the poly(A)-specific ribonuclease PARN, whose DEDD-type nucle-
ase domain is closely related to that of Caf1,19,20 non-nucleoside
inhibitors have only been reported for a limited number of
Mg2+-dependent ribonucleases. These include influenza RNA
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Figure 1. Discovery of 3-hydroxy-pyrimidine-2,4-dione compounds as inhibitors of
the Caf1 ribonuclease. (A) Possible interaction modes of 3-hydroxy-pyrimidine-2,4-
dione compounds with two divalent metal ions in the active site of Caf1. (B)
Structure and activity of compounds selected from the Open Chemical Repository
Collection (NCI, Bethesda). IC50 values refer to inhibition of Caf1. Also indicated is
the standard error of the mean (n = 3).
Table 1
Activity of 7-substituted 1-hydroxy-3,7-dihydro-1H-purine-2,6-diones 5
Cmpd
R1 in 
IC50 (lM)a (Caf1) IC50 (lM)a (PARN)
5a 10.4 ± 0.4 84.1 ± 6.7
5b 28.2 ± 7.6 n.d.
5c 10.6 ± 2.7 119 ± 25
5d 6.6 ± 0.7 125 ± 32
5e 23.3 ± 2.2 245 ± 20
5f 13.3 ± 2.3 n.d.
5g 20.6 ± 5.8 n.d.
5h 3.6 ± 1.1 n.d.
5i 10.6 ± 4.3 n.d.
5j 1.5 ± 0.3 n.d.
5k 4.0 ± 1.1 n.d.
a IC50 values were determined using a fluorescence-based biochemical assay as
described.22 Also indicated are the standard errors of the means (n = 3). N.d., not
determined.
4220 G. P. Jadhav et al. / Bioorg. Med. Chem. Lett. 25 (2015) 4219–4224endonuclease (required for viral transcription) and human immun-
odeficiency virus (HIV) RNAse H (an RNA endonuclease involved in
the degradation of RNA strands of RNA:DNA hybrids).21,22 In addi-
tion, we recently reported the discovery of non-nucleoside inhibi-
tors of Caf1, which were identified by screening a compound
library.22 Here, we describe an alternative approach, based on the
discovery of N-hydroxyimide compounds as inhibitors of HIV
RNAse H and human flap endonuclease FEN1, a structure-specific
DNA endonuclease.23,24 It was suggested that these compounds
inhibited enzyme activity by coordination of the two divalent
metal ions required for catalysis (Fig. 1A). Interestingly, N-hydrox-
yimides were also identified as inhibitors of the influenza RNAScheme 1. Synthesis of 7-substituted 1-hydroxy-3,7-dihydro-1H-purine-2,6-diones. R
(ethoxymethylene)cyanamide, THF, D, 16 h, then KOBut, EtOH, D, 2 h (46–80% over 2 step
over 2 steps); (d) Pd(OAc)2, PPh3, HCOOH, EtOH–H2O (8:2), 80 C, 2 h (23–55%); (e) CDI, P
(f) R2X (X = Br or I), K2CO3, DMF, 80 C, 2–12 h, (67–98%); (g) H2, 10% (w/w) Pd(C), CH2Cl2
3 h (33%). For definitions of R1 and R2 refer to Tables 1–3.endonuclease PA.21 Based on the distance between the Mg2+
ions in the active site of the Caf1 ribonuclease (3.9–4.0 Å;
Fig. 2a and b),25 we hypothesized that compounds containing this
moiety may adopt a similar binding mode in the active site of Caf1,
thereby blocking substrate binding.
We therefore searched the Open Chemical Repository
Collection, a diverse set of more than 200,000 compounds
(Developmental Therapeutics Program, National Cancer Institute,
Bethesda), for the presence of N-hydroxyimides. To limit the num-
ber of compounds, we focused on 3-hydroxypyrimidine-2,4-diones
and obtained seven compounds for further analysis. Following
LC–MS and solubility analysis, five compounds were evaluatedeagents and conditions: (a) ethyl 2-bromoacetate, CHCl3, rt, 2 h (37–79%); (b)
s); (c) CDI, PhMe, D, 2 h, then O-allylhydroxylamine, aq NaOH, EtOH, D, 2 h (21–61%
hMe, D, 2 h, then O-benzylhydroxylamine, aq NaOH, EtOH, D, 2 h (74% over 2 steps);
–MeOH (1:9) (33–53%); (h) urea, 2-methoxyethanol, 190 C, 24 h, then aq NaOH, D,
Figure 2. Molecular modelling of inhibitors in the active site of Caf1. Complex crystal structures of human Caf1 (a; PDB 4GMJ.B)25 and PARN (b; PDB 2A1R)30 show that the
cognate poly(A) ligand (stick models) likely binds in a similar manner to the active site (protein surface with Mg2+ ions as green spheres), despite the fact that the active sites
in Caf1 and PARN have somewhat different shapes. In (c) it can be seen that the top-ranking poses of the most potent compounds 5j (magenta), 8e (cyan), and 8j (green) adopt
very similar conformations upon docking to the 4GMJ.B model, whereas several poses with similar scores were recorded for lead compound 5a (yellow), whereof only some
(one shown) were similar to the bound conformations of the more potent compounds. Probable polar binding contacts of the most potent compound 8j with the Caf1 active
site include a cation–p interaction between one of the Mg2+ ions and the phenyl ring of the inhibitor, as well as H-bonds and polar interactions involving the 3 amine and one
of the carbonyl O and the OH of the N-hydroxyimide group as indicated (d; dashed lines). Furthermore, 8jmakes numerous van-der-Waals contacts with residues (labelled in
d) of the active site cavity.
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biochemical assay (Fig. 1B).22 Interestingly, whereas compound
NSC-86353 was found to inhibit Caf1 (IC50 = 22.8 ± 0.1 lM), substi-
tution of the benzyl moiety with a methyl group at the N7 position
(NSC-85703) reduced the inhibitory activity >10-fold.
Based on this observation, we first explored the activity of
7-substituted 1-hydroxy-purine-2,6-diones 5 further. The synthesis
of these compounds was accomplished by amination (with amines
1) of ethyl 2-bromoacetate to provide the N-substituted ethyl
2-aminoacetate intermediates 2 (Scheme 1). These were
N-alkylated with (ethoxymethylene)cyanamide26 and the resulting
cyanoformamidine adducts were cyclised in situ27 with KOBut to
the 3-subsituted ethyl 5-aminoimidazole-4-carboxylates 3. The
1-allyloxy-purinedione system of the bicyclic compounds 4 was
then formed by cyclisation of intermediates 3 with the aid of car-
bonyldiimidazole (CDI) and O-allylhydroxylamine.28 The target
compounds 5 were obtained following reductive deprotection of
precursors 4.29
Starting with 7-benzylpurinedione 5a (Table 1), we hypothe-
sised that the N7-benzyl substituent binds into the hydrophobicCaf1 active site pocket delineated by residues Phe156, Leu209, and
His225 (Fig. 2c and d).31–33 Based on this hypothesis, we introduced
comparatively bulky lipophilic groups at N7. Replacement of the
benzyl with a cyclohexyl group (5b) reduced activity nearly 3-fold,
in line with what we observed upon substituting the benzyl with a
simple methyl group (see above). More conservative replacements
of the benzyl with pyridylmethyl groups afforded active com-
pounds, especially for the 2- and 3-pyridylmethyl analogues 5c
and 5d, whereas the 4-pyridylmethyl isomer 5e was less active.
Lengthening of the alkyl linker between the phenyl group and N7
from CH2 (5a) to (CH2)2 (5j) and (CH2)3 (5f) showed maximal activ-
ity for the phenethyl derivative 5j. This observation is in line with
the modelled Caf1 binding poses of compounds containing the
phenethyl group (Fig. 2c). These poses suggest an optimal
cation–p interaction between one of the Mg2+ ions and the phenyl
ring in the case of a 2-carbon linker, while maintaining hydropho-
bic interactions of the phenyl ring with Leu209. Similar dual
interactions with the Caf1 active site are not possible with 1- and
3-carbon linkers between the phenyl ring and N7. Replacement of
the benzyl group with a long-chain lipophilic substituent
Table 2
Activity of 3-substituted-1-hydroxy-7-phenethyl-3,7-dihydro-1H-purine-2,6-diones
8
Cmpd
R2 in 
IC50a (lM) (Caf1) IC50a (lM) (PARN)
8a CH3 9.3 ± 1.7 n.d.
8b CH2(CH2)2Ph 2.1 ± 0.3 n.d.
8c CH2CH3 12.2 ± 3.5 n.d.
8d CH2(CH2)3CH3 4.8 ± 1.2 n.d.
8e 1.7 ± 0.4 n.d.
8f CH2(CH2)7CH3 9.9 ± 3.6 n.d.
8g CH2(CH2)8CH3 20.7 ± 6.7 n.d.
8h CH2(CH2)10CH3 29.5 ± 22.4 n.d.
8i CH2Ph 14.5 ± 0.9 n.d.
8j 0.59 ± 0.11 23.9 ± 3.7
8k 8.7 ± 0.3 n.d.
a IC50 values were determined using a fluorescence-based biochemical assay as
described.22 Also indicated are the standard errors of the means (n = 3). N.d., not
determined.
Table 3
Activity of 7-substituted 1-hydroxy-3,7-dihydro-1H-purine-2,6-diones with modified
N-hydroxyimide function
Cmpd Structure IC50a (lM) (Caf1)
4a >1000
9 >1000
13 15.1 ± 0.3
a IC50 values were determined using a fluorescence-based biochemical assay as
described.22 Also indicated are the standard errors of the means (n = 3).
4222 G. P. Jadhav et al. / Bioorg. Med. Chem. Lett. 25 (2015) 4219–4224(5g) was not productive. On the other hand, insertion of an O atom
into the linker (5i), or replacement of the phenyl group in 5j with a
2-thienyl (5h) or 2-pyridyl (5k) group, retained most of the
activity.
We next turned our attention to the purine N3-substituent in
the context of the optimal 7-phenethyl group (Table 2). Here we
envisaged that a comparatively bulky substituent may make
favourable contacts with the Caf1 active site pocket lined by
residues Phe43, Pro44, Ser112, and Leu116 (Fig. 2c and d). TheScheme 2. Synthesis of 6-hydroxy-1-phenethyl-1,4-dihydro-5H-imidazo[4,5-b]pyridin
15 min, then CaCO3, H2O, 75 C, 48 h, then H2, 10% (w/w) Pd(C), EtOAc–MeOH–AcOH (1
78 C to rt over 16 h (36%); (c) Pd(OAc)2, PPh3, HCOOH, EtOH–H2O (8:2), 80 C, 2 h (333,7-disubstituted 1-hydroxypurine-2,6-diones 8 were prepared
from the O-benzyl precursor 6, obtained by cyclisation of imidazole
3 (R1 = (CH2)2Ph) with O-benzylhydroxylamine,34 by successive
alkylation with appropriate alkyl halides and hydrogenolysis of
products 7 (Scheme 1). Introduction of a methyl (8a), ethyl (8c),
n-pentyl (8d), isohexyl (8e), n-nonyl (8f), n-decyl (8g), or n-dodecyl
group (8h) at N3 showed optimal activity for the isohexyl congener
8e, although its activity was not improved with respect to the par-
ent compound 5j. However, replacement of the isohexyl group
with the 1-(N,N-dimethylamino)prop-3-yl group (8j) resulted in a
further affinity enhancement and afforded the most potent com-
pound in our series with activity at the submicromolar level.35
Again this potency gain can be rationalised based on docking stud-
ies, which suggest that the protonated (at physiological pH) 3
amine group in 8j is H-bonded to the amide carbonyl O of Pro44,
while maintaining most of the hydrophobic interactions of the
N3-substituent compared with the isohexyl group in 8e (Fig. 2d).
According to our binding hypothesis (Fig. 2c) the N-hydroxy-
imide function, especially the C6- and N-linked O atoms, present
in all compound of the series discussed thus far, is important for
polar interactions with the Mg2+ ions coordinated in the active site
of Caf1. Additionally, we propose that the N-hydroxyl function
H-bonds to the side-chain carboxyl of Asp61. To probe this hypothesis
we tested compounds containing modified N-hydroxyimide sub-
structures (Table 3). To this end, a purine-2,6-dione derivative (9)
lacking the N-hydroxy group of compounds 5 and 8 was obtained
from intermediate 3 (R1 = Bn) by cyclisation with urea under basic
conditions (Scheme 1).34 6-Hydroxy-1-phenethyl-1,4-dihydro-
5H-imidazo[4,5-b]pyridin-5-one 13 was obtained from the
nitroimidazole precursor 10 (Scheme 2).36 A dichloromethyl group
was introduced into this compound at the 5-position using a
vicarious nucleophilic procedure with chloroform and KOBut,
followed by hydrolysis of the dichloromethyl group to the
aldehyde and reduction of the nitro function to the aminoaldehyde
11.37 This intermediate was then cyclised with ethyl allyloxyac-
etate to the imadazopyridinone 12,38 which was deprotected to
afford target compound 13. Blocking of the N-hydroxyl function
with an allyl group in the synthesis intermediate 4a, as well as
removing the N-hydroxyl group in 9, abolished activity completely,
as expected. Furthermore, omission of the C6-carbonyl oxygen in
the hydroxy-imidazopyridinone 13 reduced activity significantly,
pointing to an important contribution of this carbonyl group to
binding, as suggested by our docking studies.
The selectivity of the compounds was determined by comparing
their activities against Caf1 and two related deadenylase enzymes:
the PARN ribonuclease, which has a conserved nuclease domain
similar to that of Caf1, and Ccr4, whose biological function is
related to Caf1, but which contains a dissimilar EEP-type nuclease
domain.22 Compounds with N7 substituents containing an aro-
matic group linked via a single carbon spacer (5a and 5c–e) selec-
tively inhibited Caf1 (Fig. 3; Table 1). By contrast, the more potent
compounds 5h, 5j and 5k with N7 substituents containing an aro-
matic group linked via a two-carbon spacer facilitating optimal
cation–p interactions displayed reduced selectivity and also inhib-
ited the related deadenylase PARN. Selectivity was not improved-5-one 13. Reagents and conditions: (a) CHCl3, KOBut, THF–DMF (2:1), 100 C,
8:1:1), 55 psi, 18 h (60% over 3 steps); (b) ethyl allyloxyacetate, (Me3Si)2NLi, THF,
%).
Figure 3. Inhibition of the ribonuclease activities of (A) Caf1, (B) PARN and (C) Ccr4
by 3,7-N-substituted-1-hydroxy-3,7-dihydro-1H-purine-2,6-diones. Reactions con-
tained no enzyme (control), complete reactions (enzyme) or complete reactions in
the presence of the indicated compound. Compounds were used at 30 lM (5a–e,
8a–d, 8f), 10 lM (5h–k), or 3 lM (8e, 8j). Error bars represent the standard
deviation.
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most potent compound 8j containing an N3-1-(N,N-dimethy-
lamino)prop-3-yl group displayed reduced activity versus PARN,
suggesting that substituents in this position can contribute to
selectivity (Table 2). None of the compounds tested displayed
activity towards the EEP-type deadenylase Ccr4.
The molecules described here are structurally unrelated to the
inhibitors of Caf1 that we described before and which were identi-
fied using a combined approach involving virtual and compound
library screening.22 Compound 8j is significantly more potent
(>20-fold) than all previously identified compounds, although the
potency of the lead compound NSC-86353 (5a) is comparable to
that of NCC-00037292 (IC50 = 14.6 ± 3.1 lM), which was reported
previously.22 To the best of our knowledge, no other inhibitors of
the Caf1 deadenylase have been described to date.In summary, we discovered purine-2,6-dione derivatives as
inhibitors of the ribonucleases Caf1 and PARN. Compound 8j was
the most potent compound with a >10-fold increased activity as
compared to compound 5a, which was identified as the initial hit
compound. In addition to polar interactions involving the N-hy-
droxyimide moiety, we propose that a cation–p interaction con-
tributes to coordination of the Mg2+ ions. We conclude that these
compounds will be useful for the biochemical analysis of deadeny-
lase enzymes and contribute to the design of improved inhibitors
of the Caf1 and PARN ribonucleases with increased potency and
selectivity.
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